# Efficacy and Safety Study of Canakinumab Administered for 6 Months (24 Weeks) in Japanese Patients With Cryopyrin-associated Periodic Syndromes Followed by an Extension Phase

> **NCT00991146** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 19 (actual)

## Conditions studied

- Cryopyrin-associated Periodic Syndromes
- Familial Cold Autoinflammatory Syndrome
- Muckle-Wells Syndrome
- Neonatal Onset Multisystem Inflammatory Disease

## Interventions

- **DRUG:** canakinumab

## Key facts

- **NCT ID:** NCT00991146
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-10
- **Primary completion:** 2012-02
- **Final completion:** 2012-02
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2020-09-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00991146

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00991146, "Efficacy and Safety Study of Canakinumab Administered for 6 Months (24 Weeks) in Japanese Patients With Cryopyrin-associated Periodic Syndromes Followed by an Extension Phase". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00991146. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*